FLT3 and acute myeloid leukemia: Given that gilteritinib treatment has been reported to decrease the oxygen consumption rate in FLT3-ITD AML cells, indicating a reduction in oxidative phosphorylation [44], this may also play a role in the mechanism of action, though further investigation into this mechanism of action is beyond the scope of this manuscript.